CLINICAL TRIAL: RITUXIMAB IN THE TREATMENT OF IDIOPATHIC MEMBRANOUS NEPHROPATHY

点击翻译按钮获取中文摘要

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Purpose: This study is being done to determine if the medication Rituximab can reduce protein in the urine of patients with idiopathic membranous nephropathy. Rituximab (also called Rituxan¿) is a monoclonal antibody produced by Genentech, Inc. and Biogen IDEC Pharmaceuticals using recombinant DNA technology. Rituximab is not approved to treat idiopathic membranous nephropathy. Participants: Twenty patients with Membranous Nephropathy (MN) will participate in the study. Their participation will consist of 18 visits over a 16-month period. Procedures: This is an uncontrolled, phase 2 trial assessing the effects on proteinuria of Rituximab in 20 patients with idiopathic membranous nephropathy. The primary endpoint is the change in proteinuria from baseline to 12 months.